CD4+/CD8+ improvement after switch from a second-generation integrase inhibitor regimen to long-acting cabotegravir and rilpivirine.
Journal
AIDS (London, England)
ISSN: 1473-5571
Titre abrégé: AIDS
Pays: England
ID NLM: 8710219
Informations de publication
Date de publication:
01 Nov 2024
01 Nov 2024
Historique:
received:
07
06
2024
accepted:
22
07
2024
medline:
26
9
2024
pubmed:
26
9
2024
entrez:
26
9
2024
Statut:
ppublish
Résumé
Our study assessed the CD4+/CD8+ ratio in people with HIV (PWH) switching from a second-generation integrase inhibitor regimen to long-acting cabotegravir (CAB) and rilpivirine (RPV). Over one year, we observed a significant improvement in the CD4+/CD8+ ratio; In addition, our data showed that time spent in CAB+RPV was significantly associated with an increased CD4+/CD8+ ratio. These findings suggest that long-acting therapy may enhance immune recovery, also in treatment-experienced PWH.
Identifiants
pubmed: 39325006
doi: 10.1097/QAD.0000000000003984
pii: 00002030-202411010-00013
doi:
Substances chimiques
Rilpivirine
FI96A8X663
cabotegravir
HMH0132Z1Q
Pyridones
0
Anti-HIV Agents
0
HIV Integrase Inhibitors
0
Diketopiperazines
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1890-1892Informations de copyright
Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.
Références
Mussini C, Lorenzini P, Cozzi-Lepri A, Lapadula G, Marchetti G, Nicastri E, Cingolani A, et al. CD4+/CD8+ ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV 2015; 2:e98–e106.
Sigel K, Wisnivesky J, Crothers K, Brown ST, Rimland D, Rodriguez-Barradas MC, Gibert C, et al. Immunological and infectious risk factors for lung cancer in US veterans with HIV: a longitudinal cohort study. Lancet HIV 2017; 4:e67–e73.
Castilho JL, Bian A, Jenkins CA, Shepherd BE, Sigel K, Gill MJ, Kitahata MM, et al. CD4+/CD8+ ratio and cancer risk among adults with HIV. J Natl Cancer Inst 2022; 114:854–862.
Muccini C, Gianotti N, Diotallevi S, Lolatto R, Spagnuolo V, Canetti D, et al. One-year of long-acting cabotegravir and rilpivirine in people with HIV and a long exposure to antiretroviral therapy: data from the SCohoLART study. Open Forum Infect Dis 2024; 11:ofae326.
Herrera S, Fernandez-Felix BM, Hunt PW, Deeks SG, Sainz T, Heath SL, et al. Impact of first-line antiretroviral therapy regimens on the restoration of the CD4/CD8 ratio in the CNICS cohort. J Antimicrob Chemother 2020; 75:1604–1610.
Serrano-Villar S, Zhou Y, Rodgers AJ, Moreno S. Different impact of raltegravir versus efavirenz on CD4+/CD8+ ratio recovery in HIV-infected patients. J Antimicrob Chemother 2017; 72:235–239.
Trujillo-Rodríguez M, Muñoz-Muela E, Serna-Gallego A, Milanés-Guisado Y, Praena-Fernández JM, Álvarez-Ríos AI, Herrera-Hidalgo L, et al. Immunological and inflammatory changes after simplifying to dual therapy in virologically suppressed HIV-infected patients through week 96 in a randomized trial. Clin Microbiol Infect 2022; 28:1151.e9–1151.e16.
Llibre JM, Cahn PE, Lo J, Barber TJ, Mussini C, van Welzen BJ, et al. Changes in inflammatory and atherogenesis biomarkers with the 2-drug regimen dolutegravir plus lamivudine in antiretroviral therapy-experienced, virologically suppressed people with HIV-1: a systematic literature review. Open Forum Infect Dis 2022; 9:ofac068.